chembio is a startup bio-tech venture company that focuses on discovering and developing improved treatments that are more effective and less toxic than existing standard drugs for the treatment of fibrosis including Idiopathic Pulmonary Fibrosis (IPF) and non-small cell lung cancer (NSCLC) based on the First-in-Class Transcriptional Therapy Platform. To this end, AchemBio is based on a new approach that targets the regulation of the intracellular microenvironment that causes lung diseases (IPF, NSCLC), and the efficacy and safety of the lead substances derived from this have been verified through in-vitro and in-vivo experiments.